OKYO Pharma Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®
September 08, 2022 09:25 ET
|
OKYO Pharma LTD
NEW YORK and LONDON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO;), a biotechnology company focused on the discovery and development of novel molecules to treat...
OKYO Pharma Limited: Result of Annual General Meeting
September 07, 2022 09:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- The board of directors of OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing an innovative...
OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm
August 30, 2022 02:00 ET
|
OKYO Pharma LTD
OK-101 to treat ocular diseases, including Dry Eye Disease (DED), uveitis, allergic conjunctivitis, and ocular pain.Successful pre-IND meeting with FDA in Q1 2022 and novel speed to market...
OKYO Pharma Limited - Final audited results for the year ended 31 March 2022
August 16, 2022 02:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO) (the “Company”) is pleased to announce its final audited results for the year ended 31 March...
OKYO Pharma Limited - PDMR Dealing
June 09, 2022 02:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing an innovative approach to dry eye care and...
OKYO Pharma Limited - PDMR Dealing
May 20, 2022 02:00 ET
|
OKYO Pharma LTD
LONDON and BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a life sciences company focused on the discovery and development of novel molecules to treat...
OKYO Pharma Limited Announces Closing of Public Offering and Nasdaq Listing
May 19, 2022 16:00 ET
|
OKYO Pharma LTD
LONDON, May 19, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (“OKYO Pharma” or the “Company“), a life sciences company focused on the discovery and development of novel...
OKYO Pharma Limited - PDMR Dealing
May 18, 2022 06:35 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a biotechnology company focused on the discovery and development of novel molecules to treat...
OKYO Pharma Limited Announces Pricing of Initial Public Offering of ADSs in the U.S. with director participation
May 17, 2022 02:00 ET
|
OKYO Pharma LTD
LONDON, May 17, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), a life sciences company focused on the discovery and development of novel molecules...
OKYO Pharma Limited Announces Pricing of Public Offering and Nasdaq Listing
May 16, 2022 18:12 ET
|
OKYO Pharma LTD
LONDON, May 16, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (“OKYO Pharma” or the “Company“), a biotechnology company focused on the discovery and development of novel...